達志科技(300530.SZ):計劃在第二條新能源電池生產線上進行280Ah電芯的量產
格隆匯4月23日丨達志科技(300530.SZ)4月23日在投資者互動平台回覆稱,公司已成功完成了280Ah電芯的研發,這是公司技術創新的又一重要成果。公司計劃在第二條新能源電池生產線上進行280Ah電芯的量產。目前,公司正加緊第二條新能源電池生產線的安裝調試工作,確保產線儘快投產。在具體生產進度方面,公司將根據市場需求和產能規劃進行靈活調整,並密切關注行業發展趨勢,以滿足客户需求。公司將在關鍵節點及時公吿產線投產情況。感謝您對公司關注,謝謝!
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.